Luz Camacho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Luz Camacho has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Asdrubal Aguilera-Méndez
Instituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58030, Mexico
2 shared publications - Alfredo Saavedra-Molina
Universidad Michoacana de San Nicolás de Hidalgo
1 shared publication - Beatriz Hernández-Ochoa
Laboratorio de Investigación en Ciencias Ómicas y Epidemiología Microbiana, Hospital Infantil de México Federico Gómez, Secretaría de Salud, Mexico City 06720, Mexico
1 shared publication - Berenice Franco-Juárez
División de Neurociencias, Departamento de Neurodesarrollo y Fisiología, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
1 shared publication - Cindy Bandala
Laboratorio de Neurociencia Traslacional, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico
1 shared publication - Daniel Godínez-Hernández
Institute of Chemical-Biological Research, Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58030, Mexico
1 shared publication
Latest Publications
- Open Access
- 26 March 2026
- Published by MDPI AG in Neurology International
- Vol. 18 (4) , 64
Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives
Background: Neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis, represent a major global health burden and share convergent pathogenic mechanisms, such as mitochondrial dysfunction, oxidative stress, neuroinflammation, calcium imbalance, and neuronal loss. Despite advances in symptomatic management, effective disease-modifying therapies remain limited. Objectives: This review aims to critically synthesize mechanistic, preclinical, and clinical evidence on α-lipoic acid and biotin as candidate neuroprotective agents in neurodegenerative diseases, with emphasis on shared signaling pathways, therapeutic potential, generally favorable safety profiles, and translational limitations. Methods: A narrative and integrative review was conducted, encompassing mechanistic studies, preclinical experimental models, and clinical trials and observational studies evaluating ALA and biotin in neurodegenerative diseases. The evidence was qualitatively analyzed with attention to biological plausibility, consistency across models, and clinical relevance. Results: ALA and biotin modulate key cellular pathways implicated in neurodegeneration, including mitochondrial metabolism, redox homeostasis, inflammatory signaling, and neurovascular function. Preclinical studies consistently report beneficial effects on mitochondrial efficiency, oxidative stress, and neuroinflammatory markers. In contrast, clinical evidence remains heterogeneous, with more extensive evaluation of biotin in progressive multiple sclerosis and more limited or exploratory findings for ALA across neurodegenerative disorders. Conclusions: ALA and biotin exhibit mechanistic convergence across pathways relevant to neurodegeneration and generally favorable safety profiles. Although current evidence supports their biological plausibility as adjunctive or exploratory therapeutic strategies, clinical outcomes remain inconsistent and appear to be influenced by dosing regimens, disease stage at intervention, and endpoint selection. Well-designed clinical studies are required to define their efficacy, optimal dosing, and disease-specific applicability.
- 26 March 2026
- Published by MDPI AG in Neurology International
- Vol. 18 (4) , 64
Open AccessAlpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives
Background: Neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis, represent a major global health burden and share convergent pathogenic mechanisms, such as mitochondrial dysfunction, oxidative stress, neuroinflammation, calcium imbalance, and neuronal loss. Despite advances in symptomatic management, effective disease-modifying therapies remain limited. Objectives: This review aims to critically synthesize mechanistic, preclinical, and clinical evidence on α-lipoic acid and biotin as candidate neuroprotective agents in neurodegenerative diseases, with emphasis on shared signaling pathways, therapeutic potential, generally favorable safety profiles, and translational limitations. Methods: A narrative and integrative review was conducted, encompassing mechanistic studies, preclinical experimental models, and clinical trials and observational studies evaluating ALA and biotin in neurodegenerative diseases. The evidence was qualitatively analyzed with attention to biological plausibility, consistency across models, and clinical relevance. Results: ALA and biotin modulate key cellular pathways implicated in neurodegeneration, including mitochondrial metabolism, redox homeostasis, inflammatory signaling, and neurovascular function. Preclinical studies consistently report beneficial effects on mitochondrial efficiency, oxidative stress, and neuroinflammatory markers. In contrast, clinical evidence remains heterogeneous, with more extensive evaluation of biotin in progressive multiple sclerosis and more limited or exploratory findings for ALA across neurodegenerative disorders. Conclusions: ALA and biotin exhibit mechanistic convergence across pathways relevant to neurodegeneration and generally favorable safety profiles. Although current evidence supports their biological plausibility as adjunctive or exploratory therapeutic strategies, clinical outcomes remain inconsistent and appear to be influenced by dosing regimens, disease stage at intervention, and endpoint selection. Well-designed clinical studies are required to define their efficacy, optimal dosing, and disease-specific applicability.
- Open Access
The Role of Autophagy Genes in Energy-Related Disorders
Autophagy is a cellular catabolic mechanism that facilitates the degradation of cytoplasmic components, thereby restoring energy homeostasis and mitigating cellular damage. This process functions as a housekeeping system, essential for maintaining organismal viability under stressful conditions. Numerous studies have highlighted the role of autophagy in regulating various physiological processes, including metabolic pathways. Notably, certain autophagy-related genes may play a relevant role in metabolic disorders, extending beyond their involvement in the autophagic process, and may offer potential therapeutic avenues for treating energy-related metabolic diseases. This review summarizes the roles of various components of each autophagic complex and the regulators involved in the autophagic process. In particular, it explores the intricate relationship between autophagy and several metabolic diseases, including type 2 diabetes mellitus (T2DM), obesity, and non-alcoholic fatty liver disease (NAFLD).
Open AccessThe Role of Autophagy Genes in Energy-Related Disorders
Autophagy is a cellular catabolic mechanism that facilitates the degradation of cytoplasmic components, thereby restoring energy homeostasis and mitigating cellular damage. This process functions as a housekeeping system, essential for maintaining organismal viability under stressful conditions. Numerous studies have highlighted the role of autophagy in regulating various physiological processes, including metabolic pathways. Notably, certain autophagy-related genes may play a relevant role in metabolic disorders, extending beyond their involvement in the autophagic process, and may offer potential therapeutic avenues for treating energy-related metabolic diseases. This review summarizes the roles of various components of each autophagic complex and the regulators involved in the autophagic process. In particular, it explores the intricate relationship between autophagy and several metabolic diseases, including type 2 diabetes mellitus (T2DM), obesity, and non-alcoholic fatty liver disease (NAFLD).